If the genome-editing system CRISPR-Cas9 is biology’s precise, disciplined, Swiss army knife, its march toward the clinic is more like the roller coaster from hell. One moment it’s riding high with the promise of curing devastating genetic diseases, then its prospects plummet after the discovery of previously unsuspected risks, and the next moment it turns out those risks are either overblown or avoidable. Buy another ticket and get back on board.

On Thursday, scientists led by one of the world’s foremost gene therapy experts reported a way around one of the more worrisome obstacles: that CRISPR’d cells might be prone to becoming cancerous, as two 2018 studies suggested.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • How long before this mouse fix for CRISPR is incorporated into human trials? Sangamo’s ZFN’s already edit without p53 mutation. They are in the clinic for beta-thalassemia and sickle cell both partnered with Sanofi.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy